L 21649
Alternative Names: L-000021649; L-21649Latest Information Update: 06 Mar 2008
At a glance
- Originator Merck & Co
- Class Antineoplastics
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 06 Mar 2008 No development reported - Phase-I for Acute myeloid leukaemia in USA (unspecified route)
- 06 Mar 2008 No development reported - Phase-I for Solid tumours in USA (unspecified route)
- 23 Nov 2005 Phase-I clinical trials in Acute myeloid leukaemia in USA (unspecified route)